Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 13/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 13/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.41 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30022727 | 1.00 | ESR1 (0.52) | ESR1ESR2CYP1A2HSD17B1HSD17B2 | |
| Formic Acid SCHEMBL30464838 | 0.91 | ESR1 (0.45) | ESR1ESR2CYP1A2HSD17B1HSD17B2 | |
| SCHEMBL1246942 | 0.84 | ESR1 (0.50) | ESR1ESR2CYP1A2MEN1LMNA | |
| SCHEMBL5514174 | 0.83 | ESR1 (0.72) | ESR1ESR2CYP1A2HSD17B1HSD17B2 | |
| SCHEMBL30584082 | 0.82 | ESR1 (0.41) | ESR1ESR2CYP1A2 | |
| SCHEMBL5510033 | 0.79 | ESR1 (0.49) | ESR1ESR2CYP1A2MEN1LMNA | |
| SCHEMBL30887721 | 0.79 | ESR1 (0.55) | ESR1ESR2CYP1A2 | |
| SCHEMBL30219728 | 0.79 | ESR1 (0.49) | ESR1ESR2CYP1A2HSD17B1HSD17B2 | |
| SCHEMBL29870482 | 0.79 | ESR1 (0.49) | ESR1ESR2CYP1A2HSD17B1HSD17B2 | |
| SCHEMBL83629 | 0.78 | ESR1 (0.43) | ESR1ESR2CYP1A2HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4329757-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| WO-2022232331-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-11-03 | — | — | WO | claimed |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | CHENGDU HYPERWAY PHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4509507-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | Chengdu Hyperway Pharmaceuticals Co., Ltd. (CN) | 2025-02-19 | — | — | EP | disclosed |
| US-20250019377-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2025-01-16 | — | — | US | disclosed |
| US-20240408098-A1 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | MIRATI THERAPEUTICS, INC | 2024-12-12 | — | — | US | disclosed |
| US-20240376128-A1 | N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| WO-2024123102-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | 에스케이바이오팜 주식회사 | 2024-06-13 | — | — | WO | disclosed |
| CN-117813306-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物研发有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-4329757-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2023197984-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | 成都海博为药业有限公司 | 2023-10-19 | — | — | WO | disclosed |
| US-9079836-B2 | Compound having 2-fluorophenyloxymethane structure, a method for preparing the same, a liquid crystal composition and a liquid crystal device | DIC CORPORATION (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079836-B2 | Compound having 2-fluorophenyloxymethane structure, a method for preparing the same, a liquid crystal composition and a liquid crystal device | DIC CORPORATION (JP) | 2015-07-14 | — | — | US | disclosed |
| US-9079836-B2 | Compound having 2-fluorophenyloxymethane structure, a method for preparing the same, a liquid crystal composition and a liquid crystal device | DIC CORPORATION (JP) | 2015-07-14 | — | — | US | disclosed |
| US-20140330045-A1 | COMPOUND HAVING 2-FLUOROPHENYLOXYMETHANE STRUCTURE | DIC CORPORATION (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140330045-A1 | COMPOUND HAVING 2-FLUOROPHENYLOXYMETHANE STRUCTURE | DIC CORPORATION (JP) | 2014-11-06 | — | — | US | disclosed |
| US-20140330045-A1 | COMPOUND HAVING 2-FLUOROPHENYLOXYMETHANE STRUCTURE | DIC CORPORATION (JP) | 2014-11-06 | — | — | US | disclosed |
| WO-2013099754-A1 | COMPOUND WITH 2-FLUOROPHENYLOXYMETHANE STRUCTURE | DIC株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
| US-7425354-B2 | Photopolymerizable liquid crystal composition, its polymer or polymer composition, and optical compensation element | CHISSO CORPORATION (JP) | 2008-09-16 | — | — | US | disclosed |
| JP-2001019649-A | NEW LIQUID CRYSTAL COMPOUND, 6-FLUORO-NAPHTHALENE DEIVATIVE AND LIQUID CRYSTAL COMPOSITION CONTAINING THE SAME | DAINIPPON INK & CHEM INC | 2001-01-23 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140330045-A1 | COMPOUND HAVING 2-FLUOROPHENYLOXYMETHANE STRUCTURE | INF2, CFL1, CFD | ESR1 3566/4885ESR2 4385/4885CYP1A2 628/4885 |
| US-20250019377-A1 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | CYP11B2, CYP21A2, CYP11B1 | ESR1 3905/4885ESR2 3798/4885CYP1A2 97/4885 |
| US-20240376128-A1 | N-CYCLOPROPYLPYRIDO [4, 3-D] PYRIMIDIN-4-AMINE DERIVATIVES AND USES THEREOF | CYP4A11, CYP4B1, DHPS | ESR1 4457/4885ESR2 4627/4885CYP1A2 80/4885 |
| US-20240408098-A1 | COMBINATIONS OF KRAS G12D INHIBITORS WITH PI3Ka INHIBITORS AND RELATED METHODS OF TREATMENT | KRAS, NRAS, HRAS | ESR1 1416/4885ESR2 2674/4885CYP1A2 4497/4885 |
| US-20250206759-A1 | FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE OF FUSED RING COMPOUND | KRAS, NRAS, HRAS | ESR1 1416/4885ESR2 3346/4885CYP1A2 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.